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the study period. Controls were selected based on a propensity score methodology 
ensuring exactly the same baseline lung disease distribution between the 2 groups 
and no medical claim for PH across the entire study period. RESULTS: A total of 2,236 
cases met study criteria. On average, cases were significantly (p< 0.01) younger (67 vs. 
71), more females (64% vs 58%) and higher comorbid burden (2.8 vs 2.09) compared 
to controls. After adjusting for all baseline characteristics cases had significantly 
higher (p< 0.001) inpatient admissions (5.0 vs 2.4), physician office visits (16.5 vs 
12.5), emergency room visits (0.7 vs 0.5), pharmacy claims (67 vs 54). This translated 
into higher expenditures among cases ($42,914) vs controls ($16,745) at per patient 
per year level. CONCLUSIONS: Using health plan data this study showed that Group 
3-PH poses a significant economic burden to payers.
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OBJECTIVES: To estimate the direct medical costs of severe acute respiratory infec-
tion (SARI) in children and adults from three Central American countries whit a 
bottom-up costing approach. METHODS: The costs of inpatients treatment were 
estimated through the retrospective bottom-up costing in a randomized sample of 
clinical records from SARI patients treated in teaching tertiary hospitals during 2009 
- 2011 period. Activities incurred per patient were registered and a setting-specific 
cost per activity was acquired. Average cost per patient in the group of children and 
elderly adults was estimated for each country. In Nicaragua, only the pediatric popu-
lation was included. Costs were expressed in local currency (2011), American dollars, 
and international dollars (2005) for country comparison. RESULTS: The care cost per 
case in children in Guatemala was the cheaper (I$971.95) compared to Nicaragua 
(I$1,431.96) and Honduras (I$1,761.29). In adults, the treatment cost for Guatemala 
was the more expensive: I$4,065.00 vs. I$2,707.91 in Honduras. CONCLUSIONS: 
Bottom-up costing of SARI cases allowed the mean estimates per treated case that 
could have external validity for the target population diagnosed in hospitals with 
similar epidemiological profiles and level of complexity for the study countries. This 
information is very relevant for the decision-making.
PHS37
racial variation in tHe clinical and economic burden of Skeletal-
related eventS among elderly men witH Stage iv metaStatic 
ProState cancer
Jayasekera J.1, Onukwugha E.1, Bikov K.1, Hussain A.2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School 
of Medicine, Baltimore, MD, USA
OBJECTIVES: To investigate racial disparities in the incidence of skeletal-related 
events (SREs) and healthcare utilization costs associated with SREs among older 
African American (AA) and non-Hispanic White (NHW) men with advanced prostate 
cancer (PCa). METHODS: We identified men aged 66 or older, diagnosed with stage 
IV metastatic PCa between 2000 and 2007 from the SEER-Medicare dataset. Three 
mutually exclusive SRE categories were created for pathologic fracture (PF), spinal 
cord compression (SCC), and bone surgery (BS). Multivariable logistic regression 
models were used to assess the relationship between SREs and race, controlling 
for other demographic, clinical, and treatment characteristics. The annual unad-
justed post-SRE healthcare utilization costs included total monthly costs in the 
12-month post-period relative to the first SRE. Difference-in-difference estimates 
were derived in a propensity score matched sample to obtain annual adjusted SRE-
specific costs. We estimated unadjusted post-SRE and adjusted SRE-specific cost 
differences between AA and NHW men. RESULTS: Application of inclusion criteria 
resulted in 6,455 metastatic PCa patients with 1,035 AA and 5,420 NHW men. A 
higher proportion of NHWs (16%) experienced SREs compared to AAs (13%) (p< 0.01). 
The likelihood of experiencing SREs among AAs was lower than in NHWs after 
adjusting for individual characteristics (OR:0.81,95%CI:0.68-0.96,p= 0.02), specifi-
cally due to the lower likelihood PF and BS events among AA men. The unadjusted 
post-SRE costs among AAs were US$12,962 (95%CI:US$3,995-US$21,930;p< 0.01) 
higher compared to NHW men. However, the adjusted SRE-specific cost differ-
ences between AA and NHW men were not statistically significant. The adjusted 
SRE-specific costs were US$35,725 (95%CI:US$22,190-US$49,260) among AAs, and 
US$25,896 (95%CI:US$21,669-US$30,123) among NHWs. SRE-specific costs varied 
by SRE type, with BS costing more than PF and SCC events. CONCLUSIONS: Even 
though AA men were less likely to experience SREs than NHWs, the observed trend 
towards higher costs in advanced PCa care among AA men highlight the need for 
further research with larger, racially diverse samples.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common cancer in both 
male and female in the world. Therefore, CRC causes the high economic burden 
for both patients and society. Understanding the cost of CRC is necessary to con-
duct the relevant healthcare policies, especially in Vietnam. This is also the aim of 
this study. METHODS: A decision tree model was built to analyze the cost of each 
stage based on the National Comprehensive Cancer Network Guideline in 2013. The 
average cost of CRC was evaluated by using the following formula: COI = DC + IC. 
In which: COI - cost of illness, DC- direct cost, IC- indirect cost . The analysis was 
dration-$12,100 chemotherapy administration). For children 10-14 years, affective 
psychoses had the longest LOS (mean LOS= 7.5 days; range: 1.6 acute appendicitis-4.5 
chemotherapy administration), and chemotherapy administration had the greatest 
cost (mean cost= $13,295; range: $3,790 asthma with acute exacerbation-$11,999 acute 
appendicitis). CONCLUSIONS: Children in the US are hospitalized for a variety of 
reasons, with respiratory illnesses (i.e., pneumonia, asthma, and bronchiolitis) being 
common in all age groups. The LOS associated with the most common reasons for 
hospitalization is typically short with mean costs not exceeding $14,000.
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OBJECTIVES: Estimate direct medical costs of selected acute complications in 
patients with non-valvular atrial fibrillation (NVAF) at a private hospital “Clínica 
Santa Sofía” in Venezuela. METHODS: The hospital´s Medical Statistics Department 
was used to identify the study population. CIE-10 codes were used to identify 
patients with NVAF and select complications of AF. Complications of interest are: 
ischemic stroke, hemorrhagic stroke, systemic embolism, myocardial infarction, 
gastrointestinal hemorrhage and non-neurological hemorrhage. All cases from 2012 
-2013 meeting the inclusion criteria were reviewed. Patient level data from clinical 
charts was extracted to estimate resource utilization per patient per event. Costs 
were estimated using the hospital’s 2014 tariffs and expressed per patient in 2014 
Bolívares Fuertes (BsF). RESULTS: Mild and moderate ischemic stroke costs were 
estimated at BsF. 79,114 (SD 103,903), BsF 90,266 (SD 97,934). One case of mild, and 
one case of moderate ischemic stroke consumed high healthcare resources in this 
study population. Only one case of severe fatal ischemic stroke was identified and 
costs were estimated at BsF 14,143. No hemorragic stroke events were collected. 
Systemic embolism and myocardial infarction costs accounted for BsF 79,846 and 
BsF 36,332 (SD 13,865) respectively. Gastrointestinal hemorrhage was estimated at 
BsF 16,229 (SD 1,841) and only 1 event of non-neurological hemorrhage was col-
lected and costs estimated at BsF 8,864. CONCLUSIONS: Direct medical costs for 
NVAF patients at this private hospital increase as the severity of the event. High 
variability in costs was observed. Estimating these costs could help clinicians and 
decision makers a better understanding on the importance of preventing these 
complications with adequate NVAF treatment.
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Multiple sclerosis (MS) is an inflammatory demyelinating disease of central nerv-
ous system. It affects more than 1 million people in the world and the estimated 
prevalence in Colombia is of 4 to 5 per 100,000 inhabitants. It is a high cost disease 
and the drugs for its treatment were included to the benefit plan of health system 
since 2014.OBJECTIVES: Estimate the direct costs associated with the health care of 
patients with MS insured with a health manteinance organization (HMO) in Colombia 
during the period 2010-2014. METHODS: A retrospective cross-sectional study was 
conducted in a cohort of 163 patients distributed in 13 cities of the country and affili-
ated with a HMO in Colombia during January 2010 to December 2014. Demographic 
characteristics of the cohort are described and the average annual costs were esti-
mated by health service and patient. Costs were adjusted for inflation and expressed 
in 2014 US dollars. RESULTS: The prevalence of MS was 7.85 per 100,000 persons, the 
69.94% were female, the mean age was 40.91 years (SD 12.57 years), and cities with 
higher concentrations of patients were Bogotá (47%), Barranquilla (16%) and Medellin 
(9%). The average annual cost of care for the 163 patients was $ 2,663,500.79, mainly 
because drugs (85.39%), followed by diagnostic and therapeutic procedures (8.58%), 
magnetic resonance (1.21%), hospitalization (1.19%) and specialized consultations 
(0.92%). The average annual cost per patient was $ 21,303.43 (2010), $ 17,842.61 (2011), $ 
22,327.09 (2012), $ 22,662.90 (2013) and $ 20,205.28 (2014). CONCLUSIONS: The average 
annual cost per patient of MS in an insured population in Colombia corresponds to 
the annual premium per capita of 68 patients by 2014. Despite the change of technol-
ogy in the pharmacological treatment of these patients, there was not a significant 
increase in health care costs during the follow.
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OBJECTIVES: Pulmonary hypertension (PH) is classified into 5 groups. Group 3-PH 
is PH associated with lung diseases, such as chronic obstructive pulmonary dis-
ease (COPD), interstitial lung diseases (ILD), or those associated with sleep-related 
breathing disorders. We estimated the burden of Group 3 PH patients to US pay-
ers. METHODS: A 1:1 case-control study design using a large health insurance 
claims database was employed. Group 3-PH patients were identified using the fol-
lowing inclusion criteria: ≥ 2 medical claims for PH during July 1 2011 through June 
30 2012; at least one procedural claim for echocardiogram or right heart catheteriza-
tion, and at least one medical claim for COPD, ILD, breathing sleep disorders, alveolar 
hypoventilation disorder, chronic exposure to high altitude, or developmental lung 
diseases. Patients were excluded if they had a medical claim for left heart disease, 
pulmonary embolism, hematologic disorders, systemic disorders, metabolic disor-
ders or other categories as described in the 2013 classification of PH anytime during 
